The Blog

Resorcinol is used in thousands of products. Most companies that use it have never assessed it as an endocrine disruptor.

That gap just got smaller.

At the June 2026 RAC-77 meeting, RAC adopted a harmonised CLH opinion classifying resorcinol (1,3-benzenediol) as an endocrine disruptor for human health — Category 1 (ED HH 1; EUH380).

Category 1 means the evidence is considered established. It is the highest category under the CLP endocrine disruptor hazard class. It brings labelling obligations, supply chain communication duties and scrutiny of uses that, until now, had no ED-related compliance requirement.

For companies across rubber, cosmetics, fragrances, adhesives and tyres, this is not a future risk. The classification opinion has been adopted.

Sectors Impacted

Resorcinol’s industrial footprint is wide. The classification touches a broad range of sectors:

• Rubber and tyre manufacturing — resorcinol is used as a bonding agent in rubber-to-steel cord systems; tyre industry stakeholders were active at RAC-77
• Cosmetics and personal care — used as a skin-lightening and anti-dandruff agent; Cosmetics Europe participated in the RAC-77 discussion
• Adhesives and resins — resorcinol-formaldehyde resins are used in wood bonding, structural adhesives and composites
• Pharmaceuticals and dermatology — topical formulations for skin conditions
• Industrial coatings and surface treatments

If resorcinol appears in your raw materials, formulations or articles — directly or as a component of a resin system — this classification affects your compliance picture.

Regulatory Signals and Downstream Obligations

What the ED HH 1 classification triggers — and what comes next

• RAC-77 (June 2026): RAC adopted by consensus a harmonised CLH opinion classifying resorcinol as ED HH 1 (EUH380) — established endocrine disruptor for human health. The opinion now goes to the European Commission for entry into CLP Annex VI.
• Once listed in Annex VI, EUH380 labelling is mandatory for mixtures above the relevant concentration thresholds.
• Supply chain communication obligations follow: SDS updates, downstream user notifications, ingredient disclosure in formulations.
• Cosmetics Regulation (EC 1223/2009): An ED HH 1 classification creates pressure for restriction of resorcinol-containing cosmetics; the Commission may initiate a specific measure.
• REACH substance evaluation and restriction: ED classification is a standard trigger for further regulatory scrutiny, including potential Annex XIV (authorisation) or Annex XVII (restriction) listing consideration.
• Occupational exposure: Heightened scrutiny of workplace OEL values and exposure controls for endocrine disruptors is an ongoing EU priority.

The classification has been adopted. The downstream obligations follow automatically as it moves through the legislative process.

How REACHLaw Can Support You

An ED HH1 classification is more than a warning, it is a confirmation that new regulatory obligations are in place and that additional ones may be imposed in the future.

Companies that act now — on SDS, supply chain communication, product-level exposure assessment and substitution planning — are in a fundamentally better position than those who wait for the Commission entry.

REACHLaw’s Substance Risk Map for Resorcinol gives you a clear picture of what the classification means for your specific products, uses and markets.

We cover:

• Current regulatory status and the timeline to Annex VI listing
• Scope of the classification and concentration thresholds relevant to your products
• Sector-specific exposure assessment — cosmetics, rubber, adhesives, pharma
• Supply chain and SDS obligations triggered by the opinion
• Risk ranking and priority actions for regulatory, procurement and product teams

REACHLaw has supported companies on endocrine disruptor classifications, CLH processes and downstream regulatory strategy across the EU for nearly two decades.

Contact us to understand what the resorcinol ED classification means for your business.